- Previous Close
0.6530 - Open
0.6617 - Bid 0.6116 x 400
- Ask 0.6782 x 400
- Day's Range
0.6300 - 0.6789 - 52 Week Range
0.4120 - 4.2980 - Volume
238,181 - Avg. Volume
5,319,763 - Market Cap (intraday)
25.336M - Beta (5Y Monthly) 2.84
- PE Ratio (TTM)
-- - EPS (TTM)
-2.8400 - Earnings Date Feb 20, 2025 - Feb 24, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
0.55
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
www.athira.com65
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: ATHA
View More
Performance Overview: ATHA
Trailing total returns as of 2024-11-29, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ATHA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ATHA
View MoreValuation Measures
Market Cap
25.34M
Enterprise Value
-42.21M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-47.53%
Return on Equity (ttm)
-84.57%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-113.45M
Diluted EPS (ttm)
-2.8400
Balance Sheet and Cash Flow
Total Cash (mrq)
91.77M
Total Debt/Equity (mrq)
1.69%
Levered Free Cash Flow (ttm)
-68.05M